JP2017525776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525776A5 JP2017525776A5 JP2017530425A JP2017530425A JP2017525776A5 JP 2017525776 A5 JP2017525776 A5 JP 2017525776A5 JP 2017530425 A JP2017530425 A JP 2017530425A JP 2017530425 A JP2017530425 A JP 2017530425A JP 2017525776 A5 JP2017525776 A5 JP 2017525776A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- dementia
- pharmaceutical composition
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*=C1C=C(c2cc([s]cc3)c3cn2)OC2C=CC(CCCN3CCOCC3)=C[C@@]12 Chemical compound C*=C1C=C(c2cc([s]cc3)c3cn2)OC2C=CC(CCCN3CCOCC3)=C[C@@]12 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182468 | 2014-08-27 | ||
| EP14182468.0 | 2014-08-27 | ||
| PCT/EP2015/069601 WO2016030444A1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525776A JP2017525776A (ja) | 2017-09-07 |
| JP2017525776A5 true JP2017525776A5 (enExample) | 2017-10-19 |
| JP6430015B2 JP6430015B2 (ja) | 2018-11-28 |
Family
ID=51421865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530425A Expired - Fee Related JP6430015B2 (ja) | 2014-08-27 | 2015-08-27 | 新規クロモンオキシム誘導体、および代謝型グルタミン酸受容体のアロステリックモジュレーターとしてのそれの使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10017521B2 (enExample) |
| EP (3) | EP3186257B1 (enExample) |
| JP (1) | JP6430015B2 (enExample) |
| KR (1) | KR101870589B1 (enExample) |
| CN (2) | CN110343118A (enExample) |
| AU (1) | AU2015308438B2 (enExample) |
| CA (1) | CA2956191C (enExample) |
| CY (1) | CY1121352T1 (enExample) |
| DK (1) | DK3186257T3 (enExample) |
| ES (1) | ES2714073T3 (enExample) |
| HR (1) | HRP20190343T1 (enExample) |
| HU (1) | HUE041941T2 (enExample) |
| IL (1) | IL250287B (enExample) |
| LT (1) | LT3186257T (enExample) |
| MA (3) | MA52702A (enExample) |
| ME (1) | ME03339B (enExample) |
| MX (1) | MX369643B (enExample) |
| NZ (1) | NZ728853A (enExample) |
| PL (1) | PL3186257T3 (enExample) |
| PT (1) | PT3186257T (enExample) |
| RS (1) | RS58592B1 (enExample) |
| RU (1) | RU2672569C2 (enExample) |
| SI (1) | SI3186257T1 (enExample) |
| SM (1) | SMT201900152T1 (enExample) |
| TR (1) | TR201903332T4 (enExample) |
| WO (1) | WO2016030444A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52702A (fr) * | 2014-08-27 | 2021-03-31 | Prexton Therapeutics Sa | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| ES2764490T3 (es) * | 2015-08-27 | 2020-06-03 | Prexton Therapeutics Sa | Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa |
| AU2019309448B2 (en) | 2018-07-26 | 2024-08-29 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| JP3993651B2 (ja) * | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20070027216A1 (en) | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| CA2696016A1 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2011051478A1 (en) | 2009-10-30 | 2011-05-05 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| WO2011069063A2 (en) | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals, Inc. | Multicyclic compounds and methods of use thereof |
| WO2013107862A1 (en) * | 2012-01-18 | 2013-07-25 | Addex Pharma S.A. | NOVEL 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| MA52702A (fr) * | 2014-08-27 | 2021-03-31 | Prexton Therapeutics Sa | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| ES2764490T3 (es) | 2015-08-27 | 2020-06-03 | Prexton Therapeutics Sa | Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa |
-
2015
- 2015-08-27 MA MA052702A patent/MA52702A/fr unknown
- 2015-08-27 MA MA040530A patent/MA40530A/fr unknown
- 2015-08-27 CA CA2956191A patent/CA2956191C/en not_active Expired - Fee Related
- 2015-08-27 LT LTEP15770814.0T patent/LT3186257T/lt unknown
- 2015-08-27 SM SM20190152T patent/SMT201900152T1/it unknown
- 2015-08-27 HR HRP20190343TT patent/HRP20190343T1/hr unknown
- 2015-08-27 SI SI201530640T patent/SI3186257T1/sl unknown
- 2015-08-27 EP EP15770814.0A patent/EP3186257B1/en active Active
- 2015-08-27 MX MX2017002429A patent/MX369643B/es active IP Right Grant
- 2015-08-27 AU AU2015308438A patent/AU2015308438B2/en not_active Ceased
- 2015-08-27 CN CN201910567865.9A patent/CN110343118A/zh active Pending
- 2015-08-27 ES ES15770814T patent/ES2714073T3/es active Active
- 2015-08-27 PT PT15770814T patent/PT3186257T/pt unknown
- 2015-08-27 ME MEP-2019-59A patent/ME03339B/me unknown
- 2015-08-27 EP EP19151429.8A patent/EP3502115A1/en not_active Withdrawn
- 2015-08-27 PL PL15770814T patent/PL3186257T3/pl unknown
- 2015-08-27 CN CN201580045432.7A patent/CN106715444B/zh not_active Expired - Fee Related
- 2015-08-27 MA MA048048A patent/MA48048A/fr unknown
- 2015-08-27 DK DK15770814.0T patent/DK3186257T3/en active
- 2015-08-27 EP EP19217991.9A patent/EP3696183A1/en not_active Withdrawn
- 2015-08-27 WO PCT/EP2015/069601 patent/WO2016030444A1/en not_active Ceased
- 2015-08-27 US US15/506,941 patent/US10017521B2/en not_active Expired - Fee Related
- 2015-08-27 KR KR1020177005768A patent/KR101870589B1/ko not_active Expired - Fee Related
- 2015-08-27 TR TR2019/03332T patent/TR201903332T4/tr unknown
- 2015-08-27 RS RS20190289A patent/RS58592B1/sr unknown
- 2015-08-27 JP JP2017530425A patent/JP6430015B2/ja not_active Expired - Fee Related
- 2015-08-27 HU HUE15770814A patent/HUE041941T2/hu unknown
- 2015-08-27 RU RU2017109818A patent/RU2672569C2/ru active
- 2015-08-27 NZ NZ728853A patent/NZ728853A/en not_active IP Right Cessation
-
2017
- 2017-01-25 IL IL250287A patent/IL250287B/en active IP Right Grant
-
2018
- 2018-06-05 US US16/000,338 patent/US10442818B2/en active Active
-
2019
- 2019-03-08 CY CY20191100277T patent/CY1121352T1/el unknown
- 2019-09-30 US US16/587,670 patent/US20200024285A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524822A5 (enExample) | ||
| JP2016535786A5 (enExample) | ||
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| JP2017519807A5 (enExample) | ||
| RU2009126742A (ru) | Композиции и способы применения (r)-прамипексола | |
| MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| JP2013526544A5 (enExample) | ||
| HRP20191055T1 (hr) | Terapeutska sredstva za neurodegenerativne bolesti | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| NZ700374A (en) | New therapeutic approaches for treating parkinson’s disease | |
| EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
| JP2018507886A5 (enExample) | ||
| JP2012523430A5 (enExample) | ||
| JP2017525776A5 (enExample) | ||
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| NI201800031A (es) | Derivados de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa | |
| JP2016509030A5 (enExample) | ||
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| AR112683A1 (es) | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende | |
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| JP2018502163A5 (enExample) | ||
| JP2015534990A5 (enExample) |